Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

PORT-77, a Novel and Potent Inhibitor of ABCG2, Protects Against Skin Photo Toxicity and Liver Damage in a Mouse Model of Erythropoietic Protoporphyria (EPP)

Bhavik Shah, Edmond Huang, Yvonne Pak, Chris Henry, Sunita Babbar, Athiwat Hutchaleelaha, Robert Zamboni, Xiaochao Ma, Pete Schmidt, Morgan Paull, Uma Sinha

Blood (2024) 144 (Supplement 1): 11.

https://doi.org/10.1182/blood-2024-205391

Published: 2024

Journal Articles

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Jo Howard, Claire Jane Hemmaway, Paul Telfer, D. Mark Layton, John Porter, Moji Awogbade, Timothy Mant, Daniel D. Gretler, Kobina Dufu, Athiwat Hutchaleelaha, Mira Patel, Vincent Siu, Sandra Dixon, Noel Landsman, Margaret Tonda, Joshua Lehrer-Graiwer

Blood (2019) 133 (17): 1865–1875.

https://doi.org/10.1182/blood-2018-08-868893

Published: 2019

Journal Articles

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Carla B Washington, PhD, Michelle Green, PhD, Adlette C. Inati, MD, Clark Brown, MD PhD, Carolyn C Hoppe, MD, Winfred Wang, MD, Ganesh Balaratnam, MD, Sandra Dixon, MS, Erica Fong, Athiwat Hutchaleelaha, PhD, Margaret E Tonda, PharmD, Josh Lehrer, MD MPhil, FACC

Blood (2017) 130 (Supplement 1): 980.

https://doi.org/10.1182/blood.V130.Suppl_1.980.980

Published: 2017

Journal Articles

Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects

Peter Rademacher, PhD, Athiwat Hutchaleelaha, PhD, Carla Washington, Josh Lehrer, Eleanor Ramos, MD

Blood (2016) 128 (22): 2487.

https://doi.org/10.1182/blood.V128.22.2487.2487

Published: 2016

Journal Articles

Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor

Josh Lehrer-Graiwer, MDMPhil, FACC, Jo Howard, MB, BChir, Claire Jane Hemmaway, MD, Moji Awogbade, Paul Telfer, FRCPath,MD, Mark Layton, MB, FRCP, John B. Porter, MD, Timothy Mant, MB, FFPM, FRCP, Kobina Dufu, PhD, Athiwat Hutchaleelaha, PhD, Donna Oksenberg, PhD, Mira Patel, PhD, Margaret Eleanor Tonda, PharmD, Kenneth Bridges, MD, Eleanor Ramos, MD

Blood (2016) 128 (22): 2488.

https://doi.org/10.1182/blood.V128.22.2488.2488

Published: 2016

Journal Articles

GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species

Athiwat Hutchaleelaha, PhD, Mira Patel, PhD, Abel Silva, Donna Oksenberg, PhD, Brian Metcalf, PhD

Blood (2015) 126 (23): 2172.

https://doi.org/10.1182/blood.V126.23.2172.2172

Published: 2015

Journal Articles

GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

Josh Lehrer-Graiwer, MDMPhil, FACC, Jo Howard, MD, Claire Jane Hemmaway, MD, Moji Awogbade, Paul Telfer, FRCPath,MD, Mark Layton, MB, FRCP, Timothy Mant, MB, FFPM, FRCP, Kobina Dufu, PhD, Athiwat Hutchaleelaha, PhD, Teri Koller, MBA, Donna Oksenberg, PhD, Mira Patel, PhD, Eleanor Ramos, MD

Blood (2015) 126 (23): 542.

https://doi.org/10.1182/blood.V126.23.542.542

Published: 2015

Journal Articles

GTx011, a Potent Allosteric Modifier of Hemoglobin Oxygen Affinity, Prevents RBC Sickling in Whole Blood and Prolongs RBC Half-Life in Vivo in a Murine Model of Sickle Cell Disease

Kobina Dufu, PhD, Donna Oksenberg, PhD, Chengjing Zhou, Athiwat Hutchaleelaha, PhD, David R. Archer, PhD

Blood (2014) 124 (21): 217.

https://doi.org/10.1182/blood.V124.21.217.217

Published: 2014

Journal Articles

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Crowther Mark, MD, Mathur Vandana, MD, Kitt Michael, MD, Lu Genmin, PhD, Pamela B. Conley, Ph.D., Hollenbach Stanley, JD, Janice Castillo, Athiwat Hutchaleelaha, Ph.D., Mark Karbarz, Ph.D., Joyce P. Lin, Lee Barron, PhD, Sandra Russell, R.N, Gallia G. Levy, MD, PhD, Stuart Connolly, M.D., John T. Curnutte, MD, PhD

Blood (2013) 122 (21): 3636.

https://doi.org/10.1182/blood.V122.21.3636.3636

Published: 2013

Journal Articles

Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Athiwat Hutchaleelaha, Ph.D., Christine Ye, Ph.D., Yonghong Song, Ph.D., Todd Lorenz, MD, Daniel Gretler, MD, Joseph L Lambing, Ph.D.

Blood (2012) 120 (21): 2266.

https://doi.org/10.1182/blood.V120.21.2266.2266

Published: 2012

NARROW

PORT-77, a Novel and Potent Inhibitor of ABCG2, Protects Against Skin Photo Toxicity and Liver Damage in a Mouse Model of Erythropoietic Protoporphyria (EPP)

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Absorption, Metabolism and Excretion of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Male Subjects

Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor

GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species

GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease

GTx011, a Potent Allosteric Modifier of Hemoglobin Oxygen Affinity, Prevents RBC Sickling in Whole Blood and Prolongs RBC Half-Life in Vivo in a Murine Model of Sickle Cell Disease

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only